Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Investor Presentation (December 2010)
25 slides from Inovio Pharmaceuticals's investor presentation, December 2010
Slide 1: Developing Novel DNA Vaccines for Cancers and Infectious Diseases
Developing Novel DNA Vaccines for Cancers and Infectious Diseases NYSE Amex: INO J. Joseph Kim, Ph.D. President & CEO Page 1
Slide 2: Forward Looking Statement
Forward Looking Statement Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s tech
Slide 3: Investment Proposition: Why Inovio? Why Now?
Investment Proposition: Why Inovio? Why Now? • Vaccines and immune therapeutics - hot, growth markets • Inovio: Most exciting developer of novel vaccines • Fully integrated DNA vaccine development platform • Patent-protected next-generation vaccine design and delivery • DNA vaccines achieving indust
Slide 4: Vaccine Market: Opportunities and Challenges
Vaccine Market: Opportunities and Challenges Advantages of vaccine market • No generic competition • Controlled liability: Vaccine Injury Compensation Program • Early stage clinical benchmark for go/no go decisions Shortcomings of traditional vaccines New vaccine • Safety concerns of viral vaccines
Slide 5: Significant Potential of DNA Vaccines
Significant Potential of DNA Vaccines • Effectiveness of live virus vaccines without safety concerns • Could be used to prevent and treat • More cost-effective • Easier manufacturing & storage Sci Am 2010 Inovio’s DNA vaccine technology platform enables best-in-class immune responses through optimal
Slide 6: SynCon Universal Vaccines
SynCon™ Universal Vaccines Example: Influenza Immune responses more cross-reactive (universal) than those induced by single-strain vaccines Page 6
Slide 7: Better DNA Vaccine Delivery: Electroporation
Better DNA Vaccine Delivery: Electroporation • Efficient: up to 1000X increase in DNA uptake • No unwanted immune response against vector • No residual carrier/vector to cause toxicity • Enables potent immune responses Page 7
Slide 8: Optimized Electroporation Delivery
Optimized Electroporation Delivery • Inovio is refining electroporation delivery technology to achieve desired immune responses from different tissue targets Intramuscular Intradermal Page 8
Slide 9: Key DNA Vaccine Development Programs
Key DNA Vaccine Development Programs Clinical programs • Cervical cancer: Strong T cell immune responses in Phase I; Phase II to initiate • HIV programs: Strong T-cell immune responses in Phase I; $23.5M NIH funding Preclinical programs • Cancers & infectious diseases • Malaria: follow-on funding by
Slide 10: SynCon Universal Influenza Vaccine
SynCon™ Universal Influenza Vaccine Market/Needs • $4 billion global market • Influenza viruses classified as sub-types, e.g. H1N1, H2N2, etc., based on combination of one of 16 HA and one of 9 NA proteins • H1, H2, H3: > 90% of all human flu infection; H5: avian flu, extremely lethal • Even within
Slide 11: SynCon Universal Influenza Vaccine
SynCon™ Universal Influenza Vaccine Inovio’s universal flu vaccine: Influenza A sub-types responsible for key seasonal & pandemic • Includes key sub-types of last outbreaks of last century, plus sub-type of potential concern (H5N1) century plus dangerous new sub- type (H5N1) • Designed to protect ag
Slide 12: Inovio Universal Vaccine Protects Broadly Against H1N1
Inovio Universal Vaccine Protects Broadly Against H1N1 Protective Against Seasonal H1N1 Viruses 1918 H1N1 Pandemic Flu Challenge 2009 Pandemic Flu Challenge in Mice in Ferrets • 100% protection against world’s most • 100% protection against new pandemic severe influenza pandemic strain H1N1 strain 1
Slide 13: SynCon DNA Vaccine Program for HIV
SynCon™ DNA Vaccine Program for HIV Market/Needs • 40 million people infected with HIV worldwide • USA statistics • 1 million infected • 60,000 new infections Competition • Vaxgen protein vaccine: no effect • Sanofi Poxvirus vaccine: no effect • Merck Adenovirus vaccine: no effect • Poxvirus prime +
Slide 14: Better T Cell Responses than Viral Vaccines
Better T Cell Responses than Viral Vaccines SynCon™ DNA Vaccine + EP vs. Merck Ad5 SIV vaccines in rhesus monkeys (Ref: Molecular Therapy, 2010; Weiner et al.; UPenn/Merck/Inovio) 20000 •CD8+ CTLs (SFC/10^6 Cells) 15000 10000 5000 0 Adenoviral Vectored DNA Vaccine Only SynCon DNA + Vaccine Electopor
Slide 15: Phase I PENNVAX-B HIV Vaccine Study
Phase I PENNVAX™- B HIV Vaccine Study • SynCon™ PENNVAX™-B DNA vaccine targets HIV gag, pol, and env (clade B) • Randomized, placebo-controlled Phase I study conducted by the HIV Vaccine Trials Network (HVTN) • Total of 48 vaccinated subjects • 8 subjects received a placebo • 10 subjects received a
Slide 16: HPV, Cervical Dysplasia & Cervical Cancer
HPV, Cervical Dysplasia & Cervical Cancer Market/Needs • Cervical cancer – 99% caused by human papillomavirus • 28 – 40 M clinically pre-cancerous HPV infections globally • Worldwide: Annually • ~500,000 new cases cervical cancer – 50% fatal • 2nd largest cancer killer of women > 250k deaths • USA:
Slide 17: Inovio's Cervical Cancer Therapeutic Vaccine
Inovio’s Cervical Cancer Therapeutic Vaccine • SynCon™ VGX-3100 DNA vaccine • Targets HPV subtypes 16 & 18 • Responsible for 70% of cervical cancers • Targets E6 + E7 oncogenes • Play critical role in transforming HPV-infected cells into precancerous and cancerous cells • Three dose levels: low, mid
Slide 18: Phase I Trial Results for VGX-3100
Phase I Trial Results for VGX-3100 • Vaccine safe and well-tolerated at all doses • Significant antibody response in 83% (15 of 18) of vaccinated subjects • Significant T-cell response in 72% (13 of 18) of vaccinated subjects • High dose group: 83% (5 of 6) T-cell immune responses: strongest and mos
Slide 19: Phase II Study Design for VGX-3100 (CIN2/3)
Phase II Study Design for VGX-3100 (CIN2/3) • Randomized, blinded study: VGX-3100 with intramuscular electroporation vs. placebo control • Patients: HPV16/18+ CIN2/3 • 1ÝHQGSRLQW&,1SHUVLVWHQFHDIWHUGRVHYDFFLQDWLRQ regimen • Powered to detect efficacy: approximately 150 patients • Phase II initiation
Slide 20: Experienced Management Team
Experienced Management Team J. Joseph Kim, Ph.D. President & Chief Executive Officer Avtar S. Dhillon, M.D. Executive Chairman Mark L. Bagarazzi, M.D. Chief Medical Officer Peter D. Kies Chief Financial Officer Kevin W. Rassas Senior Vice President, Business Development Niranjan Y. Sardesai, Ph.D. S
Slide 21: Premier Advisors
Premier Advisors Scientific Advisory Board David B. Weiner, Ph.D. • Professor, Dept. of Pathology & Laboratory Medicine, U of Pennsylvania • “Father of DNA vaccines” – pioneer Iacob Mathiesen, Dr. Philos. • International electroporation technology expert Stanley A. Plotkin, M.D. • Emeritus Professor
Slide 22: Financial Information
Financial Information Financial Position Cash & short term investments (Sept. 30, 2010) $23.5 M Cash runway 1Q 2012 + At-the-Market Equity Offering (ATM) Maximum $25M; maintain 18 months cash Shares (NYSE Amex: INO) Issued & outstanding (Sept. 30, 2010) 103.5 M Page 22
Slide 23: Multiple Value-Enhancing Milestones
Multiple Value-Enhancing Milestones • VGX-3100 cervical cancer therapeutic vaccine study • Phase I: Completed • Phase II : Initiate Q1 2011 • Avian H5N1 flu vaccine (VGX-3400X) (Phase I) – Complete: Q2 2011 • Preventive HIV PENNVAX-B™ vaccine (Phase I) – Interim Result: Q4 2010 - Complete: Q2 2011 •
Slide 24: Inovio: Corporate Summary
Inovio: Corporate Summary • Inovio - most exciting new vaccine development company • Awarded “Best Early Stage Vaccine Biotech” Vaccine Industry Excellence Award, World Vaccine Congress 2010 • Dominant IP/technology position – vertically integrated platform • Best-in-class vaccine immune responses/p
Slide 25: Inovio Pharmaceuticals
Inovio Pharmaceuticals Developing the next generation of vaccines to prevent and treat cancers and infectious diseases investor.relations@inovio.com NYSE Amex: INO Page 25
Inovio Pharmaceuticals — Investor Presentation (December 2010) on 6ix